# ISAAC: a randomised trial for patients with asymptomatic advanced colorectal cancer to look at the benefits of undergoing surgical removal of their primary tumour before receiving chemotherapy for metastatic disease

Submission date	Recruitment status	[X] Prospectively registered
31/10/2008	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
21/11/2008	Completed	Results
Last Edited	Condition category	Individual participant data
19/03/2020	Cancer	Record updated in last year

## Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-surgery-chemotherapy-advanced-bowel-cancer-isaac

# Contact information

# Type(s)

Scientific

#### Contact name

Mr Austin Obichere

#### Contact details

Department of Surgery
University College London Hospital
235 Euston Road
London
United Kingdom
W1P 8BT

# Additional identifiers

**EudraCT/CTIS number** 2008-005911-16

**IRAS** number

#### ClinicalTrials.gov number

NCT01086618

## Secondary identifying numbers

UCL08/0079

# Study information

#### Scientific Title

ISAAC: a randomised trial of Initial Surgery in Advanced Asymptomatic Colorectal cancer patients receiving chemotherapy for metastatic disease

#### Acronym

ISAAC

#### Study objectives

The ISAAC trial aims to investigate whether survival is improved by resection of the asymptomatic primary tumour prior to chemotherapy compared to chemotherapy alone in patients with advanced colorectal cancer.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

South East Research Ethics Committee, 15/07/2009, ref: 09/H1102/60

## Study design

Multicentre phase II randomised controlled trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

# Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

# Health condition(s) or problem(s) studied

Colorectal cancer

#### **Interventions**

- 1. Resection of the asymptomatic primary tumour prior to chemotherapy
- 2. Chemotherapy alone

There is no prescribed treatment in this trial. The chemotherapy regimen is at the discretion of each treating clinician who may choose the standard treatment for that hospital or the patient can be entered into a chemotherapy treatment trial. The surgical treatment is at the discretion of the treating surgeon.

#### Intervention Type

Mixed

#### Primary outcome measure

Overall survival

Patients will be followed up every 3 months until death for survival and adverse events related to surgery or chemotherapy.

#### Secondary outcome measures

- 1. Morbidity of chemotherapy and surgery
- 2. Quality of life, assessed at 3 months and 6 months only
- 3. Economic evaluation

Patients will be followed up every 3 months until death for survival and adverse events related to surgery or chemotherapy.

#### Overall study start date

01/06/2009

## Completion date

31/07/2013

# Eligibility

#### Key inclusion criteria

- 1. Histologically or cytologically proven colorectal cancer
- 2. Metastases which are unresectable at presentation in the opinion of the appropriate multidisciplinary team (MDT)
- 3. Primary tumour that in the MDT's opinion does not require immediate or emergency surgery or intervention
- 4. Patients who are referred for prophylactic colonic stents are eligible
- 5. Patient considered fit for systemic chemotherapy and surgery as determined by the local colorectal cancer MDT
- 6. Adequate full blood count (haemoglobin [Hb] greater than 10.0 g/dl; white blood cell count [WBC] greater than  $3.0 \times 10^{9}$ /L; platelets [Plts] greater than  $100 \times 10^{9}$ /L)
- 7. Adequate renal biochemistry: calculated glomerular filtration rate (GFR) greater than 50 ml /min using the Wright formula or measured by ethylenediaminetetraacetic acid (EDTA) clearance
- 8. Adequate hepatobiliary function: bilirubin less than 25 mmol/l
- 9. World Health Organization (WHO) performance status of 0 or 1
- 10. If female and of childbearing potential, must have a negative pregnancy test prior to trial entry and agree to avoid pregnancy during the trial
- 11. Patients over 18 years of age (either sex) able and willing to provide written informed consent for the trial and able to comply with treatment and follow-up schedule

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

#### Target number of participants

500

#### Key exclusion criteria

- 1. Serious co-morbidity precluding systemic chemotherapy
- 2. Unresectable primary tumour
- 3. Unequivocal extensive peritoneal metastases
- 4. History of malignant disease in the preceding five years with the exception of non-melanomatous skin cancer and in situ cervical cancer
- 5. Serious medical co-morbidity, e.g. uncontrolled inflammatory bowel disease, uncontrolled angina or recent (less than six months) myocardial infarction, another serious medical condition judged to compromise ability to tolerate chemotherapy and/or surgery
- 6. Less than 18 years of age
- 7. Pregnant or breast feeding

#### Date of first enrolment

01/06/2009

#### Date of final enrolment

29/07/2011

# Locations

#### Countries of recruitment

England

**United Kingdom** 

# Study participating centre University College London Hospital

London United Kingdom W1P 8BT

# Sponsor information

#### Organisation

University College London (UK)

#### Sponsor details

Gower Street London England United Kingdom WC1E 6BT

#### Sponsor type

University/education

#### Website

http://www.ctc.ucl.ac.uk

#### **ROR**

https://ror.org/02jx3x895

# Funder(s)

# Funder type

Charity

#### **Funder Name**

Cancer Research UK (CRUK) (UK) (ref: C32436/A10431)

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Other non-profit organizations

#### Location

**United Kingdom** 

# **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration